Pre-clinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infection
A. C. Moore, E. G. Dora, N. Peinovich, K. P. Tucker, K. Lin, M. Cortese, S. Tucker
This study evaluates mucosal adenovirus vaccines against SARS-CoV-2, showing that full-length spike antigen induces stronger neutralizing antibodies and T-cell responses compared to partial antigens in mice.
bioRxiv · Sep 4, 2020 · PreprintImmunology